Homepage

111, Inc.

YI NASDAQ Categories PDF
Healthcare · Medical - Pharmaceuticals
Shanghai, 201203, China IPO 2018 111.com.cn Updated Jun 27, 3:14am
Price
$4.08
Market Cap
$35.6M
Employees
1,238
Beta
0.61
Avg Volume
19,040
CEO
Junling Liu
Business Description

Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.

Business History
Price History (1 Year)
Last updated: Jun 27, 2026 3:14am (5h ago)
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
Stock Price / EPS (Diluted)
Stock Price: $4.08
EPS (Diluted): N/A
EPS not available in income statement
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
-0.22
Stock Price: $4.08
Total Equity: N/A
Shares: N/A
Equity not available in balance sheet
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
-13.88
Market Cap: $35.64M
Total Debt: $0.00
Cash: $0.00
EBITDA: N/A
EBITDA not available
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
-$188.2M
Market Cap: $35.64M
Total Debt: $0.00
Cash: $0.00
P/S Ratio (Price per dollar of revenue)
API
Stock Price / Revenue Per Share
0.01
Stock Price: $4.08
Revenue: N/A
Shares: N/A
EV/Sales (Total value vs revenue — works when P/E can't)
API
-0.02
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
5.8%
Gross Profit: N/A
Revenue: N/A
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
-0.1%
Operating Income: N/A
Revenue: N/A
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
-0.1%
Net Income: N/A
Revenue: N/A
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
13.9%
Net Income: N/A
Total Equity: N/A
Equity not in balance sheet
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
-39.0%
Operating Income: N/A
Tax Rate: N/A
Equity: N/A
Total Debt: $0.00
Cash: $0.00
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
1.09
Current Assets: N/A
Current Liabilities: N/A
Debt/Equity (Leverage — debt vs equity)
Total Debt / Total Equity
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: N/A
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
Revenue: N/A
Shares: N/A
Missing from API: Revenue, Shares
Book Value/Share (Net assets per share)
(Total Assets - Total Liabilities) / Shares
Total Equity: N/A
Shares: N/A
Missing from API: Total Equity, Shares
FCF/Share (Real cash generated per share)
(Operating Cash Flow + CapEx) / Shares
Operating CF: N/A
CapEx: $0.00
Shares: N/A
Missing from API: Operating CF, Shares
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.08
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
Dividends Paid: N/A
Net Income: N/A
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares YI against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement

Requires paid FMP plan for this ticker

Analyst Estimates (Annual)
Last updated: Jun 27, 2026 3:14am (5h ago)
Metric 2024 2025 2026 2027
Revenue $14.5B
$14.5B – $14.5B
$15.5B
$15.5B – $15.5B
$17.7B
$17.7B – $17.7B
$20.4B
$20.4B – $20.4B
EBITDA -$261.5M
-$261.5M – -$261.5M
-$279.4M
-$279.4M – -$279.4M
-$319.5M
-$319.5M – -$319.5M
-$366.9M
-$366.9M – -$366.9M
Net Income $212.2M
$212.2M – $212.2M
$0 $0 $0
EPS
Insider Trading (Recent)
Last updated: Jun 27, 2026 3:14am (5h ago)
Type codes PPurchase SSale AAward / grant MOption exercise FIn-kind (tax) CConversion GGift DReturn to issuer
All SEC Form 4 codes
Open market
P Purchase
Open-market or private purchase of shares.
S Sale
Open-market or private sale of shares.
Compensation (Rule 16b-3)
A Award / grant
Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
D Return to issuer
Securities disposed back to the company under Rule 16b-3.
F In-kind (tax)
Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
I Discretionary
Discretionary transaction under an employee plan — Rule 16b-3(f).
M Option exercise
Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
C Conversion
Conversion of a derivative security into the underlying shares.
E Short expiration
Expiration of a short derivative position.
H Long expiration
Expiration or cancellation of a long derivative position with value received.
O OTM exercise
Exercise of an out-of-the-money derivative.
X ITM exercise
Exercise of an in-the-money or at-the-money derivative.
Other exempt
G Gift
Bona fide gift of securities.
L Small acquisition
Small acquisition under Rule 16a-6.
W Inheritance
Acquisition or disposition by will or the laws of descent.
Z Voting trust
Deposit into or withdrawal from a voting trust.
Other
J Other
Other acquisition or disposition (explained in a Form 4 footnote).
K Equity swap
Transaction in an equity swap or similar instrument.
U Tender / buyout
Disposition via tender of shares in a change-of-control transaction.

Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.

Date Insider Type Shares Price Value
2026-06-12 Chen Yang Luke S-Sale 49,920.00 $0.23 $11,482
2026-06-15 Chen Yang Luke S-Sale 44,000.00 $0.23 $10,120
2026-06-15 Sun Jian David S-Sale 58,800.00 $0.23 $13,524
2026-06-11 Sun Jian David S-Sale 111,100.00 $0.23 $25,553
2026-06-09 Sun Jian David S-Sale 12,000.00 $0.23 $2,760
2026-06-10 Sun Jian David S-Sale 115,440.00 $0.22 $25,397
2026-05-12 Luo Jun Justin A-Award 413,168.00 $0.00 $0
2026-05-26 Luo Jun Justin S-Sale 29,280.00 $0.27 $7,906
2026-05-27 Luo Jun Justin S-Sale 70,440.00 $0.25 $17,610
2026-05-11 Luo Jun Justin A-Award 378,737.00 $0.00 $0
2018-09-12 Luo Jun Justin A-Award 18,366.00 $0.00 $0
2026-05-12 Sun Jian David A-Award 413,168.00 $0.00 $0
2026-05-26 Sun Jian David S-Sale 29,280.00 $0.27 $7,906
2026-05-27 Sun Jian David S-Sale 70,440.00 $0.25 $17,610
2026-05-11 Sun Jian David A-Award 378,737.00 $0.00 $0
2018-09-12 Sun Jian David A-Award 18,366.00 $0.00 $0
2026-05-12 Chen Yang Luke A-Award 413,168.00 $0.00 $0
2026-05-26 Chen Yang Luke S-Sale 1,440.00 $0.27 $389
2026-05-27 Chen Yang Luke S-Sale 3,400.00 $0.25 $850
2026-05-11 Chen Yang Luke A-Award 54,759.00 $0.00 $0
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for YI — it's generated by the pipeline (market-narrative step).
Community AI Feedback
No community reviews yet for YI. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30